Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Echo IQ Limited engages in the provision of artificial intelligence (AI) diagnostics tool that enhance the diagnosis of structural heart disease in Australia. It offers EchoSolv, provides an AI-powered risk assessment of structural heart disease, including aortic stenosis, diastolic dysfunction, and heart failure. The company was formerly known as Houston We Have Limited and changed its name to EchoIQ Limited in December 2021. Echo IQ Limited is based in Claremont, Australia.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of EIQ.AX is 1.5 and suggests 8.64% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to